Compare Cognizant Technology Solutions Corp (CTSH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Cassava Sciences Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.82 (market cap $27.03B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Cognizant Technology Solutions Corp is far larger — about 686× Cassava Sciences Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Cassava Sciences Inc for 37 Days on average.
| CTSH | FLNA | |
|---|---|---|
Market Cap | $27.03B | $39.40M |
Volume | 9,883,888 | 759,018 |
Sector | Technology | Health |
52-Week High | $86.70 | $4.64 |
52-Week Low | $38.73 | $0.68 |
Typical Hold Time | 57 Days | 37 Days |
Enterprise Value | $28.08B | -$43.28M |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 12.25 and EV/EBITDA of 6.52, while maintaining solid profitability with 10.26% net margin. Recent news highlights the company's AI transformation initiatives and recognition as a top employer, though Q2 2026 earnings missed expectations.
CTSH presents a compelling value opportunity with strong fundamentals and analyst consensus target of $64.25 (12.6% upside). Risks include IT spending pressures from AI disruption and competitive threats. The upcoming Q3 2026 earnings report on October 29, 2026 will be critical for validating the company's growth trajectory amid industry headwinds.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
